Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 5/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 6/20 | 0.43 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4456538 | 1.00 | PGR (0.51) | PGRKCNH2ARHDAC8HDAC6 | |
| SCHEMBL3024408 | 0.91 | PGR (0.51) | PGRKCNH2ARHDAC8HDAC6 | |
| SCHEMBL3031987 | 0.88 | AR (0.43) | PGRKCNH2ARHDAC8HDAC6 | |
| SCHEMBL3032968 | 0.86 | HDAC8 (0.43) | PGRARHDAC8HDAC6DPP4 | |
| SCHEMBL4462363 | 0.86 | HDAC8 (0.43) | PGRARHDAC8HDAC6DPP4 | |
| SCHEMBL3025089 | 0.85 | TNF (0.47) | PGRARHDAC8HDAC6DPP4 | |
| SCHEMBL3028354 | 0.85 | HDAC8 (0.42) | PGRKCNH2ARHDAC8HDAC6 | |
| SCHEMBL3029493 | 0.84 | PGR (0.48) | PGRKCNH2ARHDAC8HDAC6 | |
| SCHEMBL4453837 | 0.84 | PGR (0.48) | PGRKCNH2ARHDAC8HDAC6 | |
| SCHEMBL3032986 | 0.83 | PGR (0.42) | PGRARHDAC8HDAC6RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049104-B1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2049104-B1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2012-09-19 | — | — | EP | disclosed |
| US-7816395-B2 | Pyrrolidinone anilines as progesterone receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816395-B2 | Pyrrolidinone anilines as progesterone receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816395-B2 | Pyrrolidinone anilines as progesterone receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
| EP-2049104-A2 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | SmithKline Beecham Corporation (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008021796-A2 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080039517-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC | 2008-02-14 | — | — | US | disclosed |
| US-20080039517-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC | 2008-02-14 | — | — | US | disclosed |
| US-20080039517-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039517-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC2, PGRMC1 | PGR 1/4885KCNH2 2798/4885AR 14/4885 |
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC2, PGRMC1 | PGR 1/4885KCNH2 2798/4885AR 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.